The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.

Publikation

The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.

Wissenschaftlicher Artikel/Review - 25.05.2022

Egan Allyson C, Kronbichler Andreas, Neumann Irmgard, Bettiol Alessandra, Carlson Nicholas, Cid María C, Emmi Giacomo, Gopaluni Seerapani, Harper Lorraine, Hauser Thomas, Little Mark A, Luqmani Raashid A, Mahr Alfred, McClure Mark, Mohammad Aladdin J, Nelveg-Kristensen Karl Emil, Ohlsson Sophie, Peh Chen Au, Rutherford Matthew, Alamo Beatriz Sanchez, Scott Jennifer, Segelmark Mårten, Smith Rona M, Szpirt Wladimir M, Tomasson Gunnar, Trivioli Giorgio, Vaglio Augusto, Walsh Michael, Wester Trejo Maria, Westman Kerstin, Bajema Ingeborg M, Jayne David R W

Zitation

Egan A, Kronbichler A, Neumann I, Bettiol A, Carlson N, Cid M, Emmi G, Gopaluni S, Harper L, Hauser T, Little M, Luqmani R, Mahr A, McClure M, Mohammad A, Nelveg-Kristensen K, Ohlsson S, Peh C, Rutherford M, Alamo B, Scott J, Segelmark M, Smith R, Szpirt W, Tomasson G, Trivioli G, Vaglio A, Walsh M, Wester Trejo M, Westman K, Bajema I, Jayne D. The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney Int Rep 2022; 7:1745-1757.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Kidney Int Rep 2022; 7

Veröffentlichungsdatum

25.05.2022

eISSN (Online)

2468-0249

Seiten

1745-1757

Kurzbeschreibung/Zielsetzung

The first European Vasculitis Society (EUVAS) meeting report was published in 2017. Herein, we report on developments in the past 5 years which were greatly influenced by the pandemic. The adaptability to engage virtually, at this critical time in society, embodies the importance of networks and underscores the role of global collaborations. We outline state-of-the-art webinar topics, updates on developments in the last 5 years, and proposals for agendas going forward. A host of newly reported clinical trials is shaping practice on steroid minimization, maintenance strategies, and the role of newer therapies. To guide longer-term strategies, a longitudinal 10-year study investigating relapse, comorbidity, malignancy, and survival rates is at an advanced stage. Disease assessment studies are refining classification criteria to differentiate forms of vasculitis more fully. A large international validation study on the histologic classification of anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis, recruiting new multicenter sites and comparing results with the Kidney Risk Score, has been conducted. Eosinophilic granulomatosis with polyangiitis (EGPA) genomics offers potential pathogenic subset and therapeutic insights. Among biomarkers, ANCA testing is favoring immunoassay as the preferred method for diagnostic evaluation. Consolidated development of European registries is progressing with an integrated framework to analyze large clinical data sets on an unprecedented scale.